QUESTO HUB

QUESTO HEALTHCARE ECOSYSTEM Clinical Pharmacology & Maternal-Fetal Drug Safety Center

Document ID: Q-PREG-65958036

Date Issued: October 07, 2026

Regulatory Base: US FDA (PLLR 8.1/8.2) & NIH LactMed®

Verified Portal: questocomm.com/pregnancy-safety/escitalopram

OFFICIAL CLINICAL MONOGRAPH

ESCITALOPRAM

Evidence-Based Medication Safety Profile for Maternal & Lactation Practice

Pregnancy & Lactation Center

Clinical Monograph Prescription / OTC (Escitalopram Oral Solution)

Regulatory Boxed Warning

Escitalopram

UNII Code 5U85DBW7LO

RxNorm CUI 351285

Prescribing & Clinical Reference: Compiled from official regulatory labeling (US FDA PLLR, NIH LactMed®, EMA). Clinical decisions during pregnancy and lactation require individualized patient assessment and physician consultation.

1. Pregnancy Evidence & Regulatory Labeling

FDA Pregnancy and Lactation Labeling Rule (PLLR 8.1) & EMA SmPC Section 4.6

Clinical Risk Summary

Regulatory Warnings & Contraindications

FDA Boxed Warning: This medication carries an official Boxed Warning regarding embryo-fetal toxicity or pregnancy-related adverse outcomes.

4 CONTRAINDICATIONS Escitalopram is contraindicated in patients: taking MAOIs with escitalopram or within 14 days of stopping treatment with escitalopram because of an increased risk of serotonin syndrome. The use of escitalopram within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [ see Dosage and Administration (2.7) and Warnings and Precautions (5.2) ]. Starting escitalopram in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [ see Dosage and Administration (2.6) and Warnings and Precautions (5.2) ]. taking pimozide [ see Drug Interactions (7) ] with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in escitalopram. Do not use MAOIs intended to treat psychiatric disorders with escitalopram or within 14 days of stopping treatment with escitalopram. Do not use escitalopram within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start escitalopram in a patient who is being treated with linezolid or intravenous methylene blue ( 4 ) Concomitant use of pimozide ( 4 ) Known hypersensitivity to escitalopram or citalopram or any of the inactive ingredients ( 4 )

2. Lactation & Breastfeeding Safety

NIH / NLM LactMed® Database & FDA Labeling Section 8.2

Summary of Use during Lactation

Review infant exposure and nursing considerations before administration.

Drug Levels in Breast Milk & Relative Infant Dose

Relative Infant Dose (RID) Indexed in Clinical Studies RID <10% is generally considered low by clinical guidelines.

Milk Concentration & Transport

Evaluated in human/animal pharmacokinetic models.

3. Females & Males of Reproductive Potential

FDA Labeling Section 8.3 — Pregnancy Testing, Contraception & Infertility

Pregnancy Testing

Standard pre-treatment clinical assessment as indicated.

Contraception & Washout

Review contraception duration based on drug elimination half-life.

Infertility Considerations

No significant drug-induced impairment reported in standard models.

4. Regulatory Source Provenance & Comparison

Direct attribution to official regulatory documents without synthesized consensus

Regulatory Organization	Jurisdiction	Document / Framework	Effective Date	Official Source Link
U.S. Food and Drug Administration (FDA) FDA Prescribing Information (PLLR)	United States	regulatory_label	2025-03-05	Official Record
European Medicines Agency (EMA) EMA Summary of Product Characteristics (SmPC 4.6)	European Union	regulatory_label	Recent	Official Record

U.S. Food and Drug Administration (FDA) FDA Prescribing Information (PLLR)

United States

Framework: regulatory_label

Effective Date: 2025-03-05

View Official Regulatory Record

European Medicines Agency (EMA) EMA Summary of Product Characteristics (SmPC 4.6)

European Union

Framework: regulatory_label

Effective Date: Recent

View Official Regulatory Record

Search Another Medication

Clinical Reviewer / Attending Pharmacist:

Hospital / Practice Facility:

Verification Date:

OFFICIAL CLINICAL NOTICE: This monograph is compiled from official U.S. FDA Prescribing Information (PLLR 21 CFR 201.57 Section 8), NIH / NLM LactMed®, and EMA Summary of Product Characteristics (SmPC 4.6). This document is intended solely for reference by licensed healthcare professionals and does not supersede individualized clinical judgment.